Company: VCYT
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001384101-25-000130
Chunk: 131

Company: VERACYTE, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 2
Chunk 131
---
,204 2,939 265 9 %9,989 8,694 1,295 15 %Total$33,777 $29,029 $4,748 16 %$94,444 $82,928 $11,516 14 %Cost of product revenue:        Product costs$1,050 $545 $505 93 %$1,864 $2,436 $(572)(23)%License fees and royalties257 270 (13)(5)%888 1,021 (133)(13)%Depreciation and amortization110 222 (112)(50)%471 659 (188)(29)%Other expenses1,562 528 1,034 196 %2,509 1,713 796 46 %Allocations36 227 (191)(84)%454 481 (27)(6)%Total$3,015 $1,792 $1,223 68 %$6,186 $6,310 $(124)(2)%Cost of biopharmaceutical and other revenue:        Compensation expense$426 $1,424 $(998)(70)%$3,318 $4,958 $(1,640)(33)%License fees and royalties— — — NM— 150 (150)(100)%Depreciation and amortization10 48 (38)(79)%109 172 (63)(37)%Other expenses602 976 (374)(38)%3,009 2,922 87 3 %Allocations53 664 (611)(92)%925 1,560 (635)(41)%Total$1,091 $3,112 $(2,021)(65)%$7,361 $9,762 $(2,401)(25)%Intangible asset amortization - cost of revenue$2,707 $2,917 $(210)(7)%$7,959 $8,741 $(782)(9)%

Cost of testing revenue increased $4.7 million, or 16%, for the three months ended September 30, 2025 compared to the same period in 2024. The increase in cost of testing revenue was due to increased volume in testing, higher staffing to support higher volume and the build out of infrastructure related to current and future